Pursuit Vascular Outlines Expansion Plans

MAPLE GROVE, Minn., Oct. 2, 2018 /PRNewswire/ -- Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, the leading antimicrobial device for catheter-based dialysis patients, today announced that the company has significantly expanded its sales and customer support organization.  Rapid acceptance of the company's flagship ClearGuard HD product throughout the US has resulted in the need to invest in staff to support growing customer requests.  ClearGuard HD caps are used in place of standard caps and connectors to prevent central-line associated bloodstream infections (CLABSIs).

The company recently expanded operations to include Dallas, TX; Atlanta, GA; and Philadelphia, PA, to complement its existing sales and headquarters location in Minneapolis, MN.  A national team of experienced sales representatives are now in place to service customers from coast to coast.  Support for customers in Canada will follow as regulatory approval is secured.

In addition, the company is announcing its intent to begin distribution of ClearGuard HD in overseas markets, with a tentative target of beginning sales in the European Union in the 2^nd half of 2019.  The company is actively pursuing CE-Mark regulatory approval in Europe, and has filed all necessary applications to begin the process.

Supporting this investment and expansion was the recent allowance by the US Patent and Trade Office of the company's 8^th patent for its novel ClearGuard technology platform. 

"Due to the exciting clinical study results, we're seeing rapid uptake of ClearGuard HD caps nationally across a wide range of providers to include outpatient, hospital inpatient, and long-term acute care settings," said Doug Killion, Pursuit Vascular President and CEO.  "In two different clinical trials, ClearGuard HD caps have been proven to reduce CLABSIs by ~70%.  This revolutionary technology represents a breakthrough for dialysis patients and their families."

ClearGuard HD is now available nationally.  Visit the company's website for more information.

About the ClearGuard HD Antimicrobial Barrier Cap

The ClearGuard HD Antimicrobial Barrier Cap is the first and only device cleared for sale in the U.S. that kills infection-causing bacteria inside a long-term hemodialysis catheter hub.  The caps are simple to use and clinically shown to reduce central line-associated bloodstream infection.  This simple, yet revolutionary single-use device is protected by 8 issued U.S. patents, and several other U.S. patents pending.  Foreign patents issued and pending.  For more information, visit www.clearguardhd.com.

About Pursuit Vascular

Headquartered in Maple Grove, Minnesota, Pursuit Vascular, Inc. (www.pursuitvascular.com) is developing a family of innovative products designed to protect patients from acquiring life-threatening infections associated with long-term catheter and port use, while reducing the costs of health care. 

Connect with us at www.pursuitvascular.com and on Twitter at @ClearGuardHD. 

SOURCE Pursuit Vascular

Related Links

http://www.pursuitvascular.com